CLINICAL TRIALS PROFILE FOR FYARRO
✉ Email this page to a colleague
All Clinical Trials for FYARRO
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05840510 ↗ | Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19) | Not yet recruiting | Aadi Bioscience, Inc. | Phase 1/Phase 2 | 2023-05-31 | This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation. |
NCT05840510 ↗ | Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19) | Not yet recruiting | Mirati Therapeutics Inc. | Phase 1/Phase 2 | 2023-05-31 | This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FYARRO
Condition Name
Clinical Trial Progress for FYARRO
Clinical Trial Phase
Clinical Trial Sponsors for FYARRO
Sponsor Name